Telomerase is a ribonucleoprotein complex of which the function is to add telomeric repeats to chromosomal ends. Telomerase consists of two essential components, the telomerase RNA template (hTR) and the catalytic subunit (hTERT). hTERT is expressed only in cells and tissues positive for telomerase activity, i.e., tumor or stem cells. The aim of this study was to use increased telomerase promoter activity in small-cell lung cancer (SCLC) gene therapy. The hTERT promoter and MycMax response elements (MMRE) in pGL3-Control vector containing SV40 enhancer resulted in strong expression of the luciferase gene only in telomerase positive and myc overexpressing SCLC cell line but not in normal human cell line. To investigate the possibility of the utilization of the MMRE, hTERT promoter, and SV40 enhancer in targeted SCLC gene therapy, adenovirus vector expressing HSV-TK controlled by the MMRE, hTERT promoter, and SV40 enhancer for the induction of telomerase positive and myc-overexpressing cancer specific cell death was constructed. SCLC cells infected with Ad-MMRE-hT-TK-enh were significantly suppressed and induced apoptosis more than those of Ad-hT-TK or Ad-hT-TK-enh infected cells. Telomerase and c-myc are activated in 6080% of SCLC, so the increased activity of telomerase promoter can be used for targeted SCLC gene therapy. These results show that the MMRE, hTERT promoter, and SV40 enhancer can be used in SCLC targeted cancer gene therapy.
Compared with other types of lung cancer, small-cell lung cancer (SCLC) has a greater tendency to be widely disseminated by the time of diagnosis and is highly aggressive, clinically characterized by rapid growth, frequent invasion, and metastasis. 1) Initially, SCLC may sensitive to chemo-and radiotherapy, but many of them will become resistant to any therapy. About 85% of SCLC tumors shows overexpression of the myc family 2) and that makes the myc genes a good target for SCLC treatment.
Telomerase is highly active in small-cell and nonsmall-cell lung cancers, 3) colorectal and gastric cancers, 4) hepatocellular carcinomas, 5) hematologic malignancies, 6) giant cell tumors of bone, 7) prostate cancers, 8) breast cancers, 9) and ovarian carcinomas. 10) Telomerase is a ribonucleoprotein which consists of several components. Among these, two components are known as to their functions: the RNA component (hTR) and the telomerase catalytic subunit (hTERT). hTR acts as a template for telomere synthesis.
11) The expression of hTR is ubiquitous in all types of human cells, regardless of the status of telomerase activity, but hTERT is expressed only in cells and tissues positive for telomerase activity, i.e., tumor or fetal cells. [12] [13] [14] Recently, the promoter region of cancer specific human telomerase reverse transcriptase was cloned and characterized. 15, 16) The promoter of hTERT was GC rich and lacked both TATA and CAAT boxes. Interestingly, transient expression assays indicated that transcription of hTERT was significantly activated in cancer cell lines but repressed in normal primary cells. Overexpression of c-Myc resulted in a significant increase in the transcriptional activity of the core promoter. 15, 16) Myc family proteins, groups of the helix-loop-heilx/leucine zipper family including c, N, and L-Myc, form heterodimers with a partner protein, Max. This Myc-Max protein complex binds to the CACGTG sequence and activates transcription. 17, 18) It is known that HSV-TK phosphorylates the nontoxic prodrug ganciclovir (GCV), which then becomes phosphorylated by endogenous kinases to GCV-triphosphate, causing chain termination and single-strand breaks upon incorporation into DNA. 19) The mechanisms linking TKand GCV-induced DNA damage to apoptosis, however, are largely unknown. Recently, it was found that TK-GCV induces accumulation of p53 and increases cell surface expression of death receptors, likely involving p53-mediated translocation of CD95 associated with CD95-L-independent formation of a death-inducing signaling complex (DISC), eventually leading to apoptosis involving the Fas-associated death domain protein (FADD) and caspases. 20) To whom correspondence should be addressed. Tel/Fax: +82-2-926-3316; E-mail: antibody@korea.ac.kr Biosci. Biotechnol. Biochem., 69 (1), [56] [57] [58] [59] [60] [61] [62] 2005 Because specific therapeutic gene expression is important in cancer gene therapy, targeted cancer gene therapy has the aim of concentrating the target therapeutic gene expression into the specific target tissue. Then it can minimize secondary effects and maximize the therapeutic index. Therefore, the feasibility of using the hTERT promoter to induce tumor-specific transgene expression in cancer gene therapy has been expected. The promoter of hTERT, telomerase catalytic subunits activated in 80$90% of lung cancers is fascinating as a cancer specific promoter. Although there are several examples of use of the hTERT promoter for targeted cancer gene therapy using adenovirus, 21, 22) the weak activity of this promoter hinders this approach to clinical research. So it is necessary to increase the activity of this promoter. 23) In this study, it was attempted to maintain the cancer specific character of the hTERT promoter and to increase the activity by use of the Myc-Max response elements and transcriptional enhancer of SV40 virus.
Materials and Methods
Cell culture. Wi-38 (human normal fibroblast) and QBI-293A (Quantum-Appligene, U.S.A., a human cell line transformed by adenovirus 5 DNA) cells were grown in DMEM (Gibco BRL, Germany) supplemented with 10% FCS (HyClone, Logan, U.S.A.), penicillin (50 units/ml), and streptomycin (50 mg/ml) in the presence of 5% CO 2 . NCI-H417 (small-cell lung cancer cells) were grown in RPMI1640 (Gibco BRL, Germany) supplemented with 10% FCS, penicillin (50 units/ml), and streptomycin (50 mg/ml) in the presence of 5% CO 2 . All cell lines except QBI-293A were obtained from the American Type Culture Collection (Manassas, VA).
Construction of report plasmids. Sense and antisense oligonucleotides for Myc-Max response elements were synthesized (Takara, Japan) as described by Eiseman's Group. 17) Two oligomers were annealed as described by Kishimoto's group. 18) This annealed fragment includes restriction endonuclease sites of Kpn I and Bgl II at the end of 5 0 and 3 0 respectively (Fig. 1A) . This fragment has four repeats containing a core sequence CACGTG, which is the binding site of Myc-Max heterodimers. The hTERT promoter region was amplified by PCR using LA-Taq polymerase (Takara, Japan) on the HeLa genomic DNA. The hTERT forward (5 0 -agatctagtggattcgcgggcacaga-3 0 ) and reverse (5 0 -aagcttagggcttcccacgtgcgcag-3 0 ) primers, both introducing Bgl II and Hind III site (underlined in the sequences respectively) were used. This region is the hTERT promoter region from À204 to +56, which contains the core promoter and two E-boxes. 16 ) PCR was carried out for 35 cycles at 94 C for 1 min, at 66 C for 1 min, and at 72 C for 1 min. pGL3-MMRE-hT-enh, which has MMRE, hTERT promoter and SV40 enhancer was constructed by replacing SV40 promoter of pGL3-Control plasmid with hTERT promoter and inserting MMRE fragments 
. Structure of Myc-Max Response Elements (MMRE, A) pGL3-MMRE-hT-TK-enh (B) and Luciferase Reporter Plasmids (C).
A core sequence CACGTG, which is the binding site of Myc-Max heterodimers, is indicated bold and in underlined type in (A).
hTERT Promoter Activity Increased by MMRE and SV40 Enhancer (Fig. 1C) . Direct dideoxynucleotide sequencing ensured correct sequence and direction.
Construction of recombinant adenovirus Ad-MMREhT-TK-enh. pGL3-MMRE-hT-TK-enh, which has MMRE, hTERT promoter, and SV40 enhancer was constructed by replacing the luciferase gene of pGL3-MMRE-hT-enh plasmid with HSV-TK (Fig. 1B) . Then the MMRE-hTERT promoter-HSV-TK-SV40 enhancer cassette was digested with Kpn I and Sal I, and ligated with Kpn I and Sal I digested pShuttle (Ad transfer vector; Quantum-Appligene, U.S.A.) and named pS-MMRE-hT-TK-enh. Then it was co-transformed with pAdEasy-1 (Quantum-Appligene, U.S.A.) into BJ5183 E. coli cells using electroporation methods. After selection on kanamycin plates, 40 colonies were selected and screened for recombinants by plasmid size and restriction enzyme analysis. Viral DNAs of candidates were tranfected in QBI-293A cells using FuGENEÔ6 (Roche, Germany) according to the manufacturer's protocol. This constructed adenovirus vector was named Ad-MMRE-hT-TK-enh. The constructed adenovirus were then purified from the lysates of infected QBI-293A cells by two rounds of CsCl gradient centrifugation. 24) Then the titers of the virus stock were determined by plaque dilution assay. 25) The recombinant virus were stored at À80 C until use. The control recombinant adenovirus Ad-hT-TK and Ad-hT-TK-enh using pGL3-Promoter and pGL3-Control, which do not have SV40 enhancer and MMRE respectively, were constructed in the same way above. The negative control vector (Ad5.CMV-Null; Ad-CMV) was purchased from Quantum-Appligene. Ad-CMV is an empty vector, which contains no coding sequences between the CMV promoter and PA (the poly adenylation site).
Luciferase assay. The selective expression of the luciferase gene in tumor cells was determined by luciferase reporter plasmid using FuGENEÔ6 (Roche, Germany) according to the manufacturer's protocol. Briefly, 10 5 cells seeded in a 35-mm tissue culture dish were exposed to a transfection mixture containing 2 mg of luciferase reporter plasmids and 0.5 mg of pSV--galactosidase control plasmid vector (Promega, U.S.A.). 48 h after transfection, luciferase assays were performed according to the manufacturer's protocols (Promega, U.S.A.) and measured with a TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA). The Simian virus 40 (SV40) promoter (pGL3-Promoter or pGL3-Control) was used as a positive control. hTERT promoter plasmids (pGL3-hT, pGL3-hT-enh) were constructed by replacing SV40 promoter with hTERT promoter. The luciferase activity of the pGL3-Promoter or pGL3-Control plasmid in each cell line was considered to be 100%. A -Galactosidase assay was also performed with the same cell extracts to standardize for transfection efficiency. All of the data shown in this study were obtained from at least three independent experiments.
Adenovirus infection with GCV treatment in vitro. 10 5 cells were plated in six-well plates prior to infection. The Ad-CMV, Ad-hT-TK, Ad-hT-TK-enh, and Ad-MMRE-hT-TK-enh adenovirus were applied in 1 ml of media at a 50 moi 24 h later. Cells were incubated at 37 C for 3 h followed by the addition of 2 ml media containing a 50 mM concentration of GCV (Ganciclovir; InvivoGen, San Diego, CA). Cell cultures were replenished every day with fresh medium containing GCV. All of the data shown in this study were obtained from at least three independent experiments.
Cell death detection ELISA. Cytoplasmic histoneassociated-DNA-fragments (mono-and oligonucleosomes) after induced cell death by Ad-MMRE-hT-TKenh and GCV were determined by Cell Death Detection ELISA PLUS (Roche, Germany). Briefly, the Ad-CMV, Ad-hT-TK, Ad-hT-TK-enh, and Ad-MMRE-hT-TK-enh infected cell lysates were placed in a streptavidin-coated micro-plate. A mixture of anti-histone-biotin and anti-DNA-POD was added and incubated for 2 h at 15-25 C. After removal of unbound antibodies by a washing step, POD was determined photometrically at 405 nm with ABTS as substrate.
Results

Variation of transcriptional activity of hTERT promoter in SCLC and normal cells
To show the variation of transcriptional activity of hTERT promoter in SCLC and normal cells, a transient transfection of luciferase repoter plasmid was performed (Fig. 2) . The transcriptional activity of pGL3-Promoter plasmid in each cell line was considered to be 100%. pGL3-hT showed significant transcriptional activity in SCLC at about 138% of pGL3-Promoter. In contrast, there was no significant transcriptional activity in the Luciferase genes were introduced into normal fibroblast (Wi-38) and a small cell lung cancer cell line (NCI-H417). Relative luciferase activity was standardized with control plasmid pGL3-Promoter transfection. The means from at least three independent experiments are shown; bars, SD. telomerase activity negative normal fibroblast cell line (Wi-38). These results showed that SCLC had strong transcriptional activity for hTERT promoter. A highly sensitive TRAP assay 26) also showed that the NCI-H417 cell line had strong telomerase activity, but not the normal cell line (Wi-38; data not shown).
Effect of MMRE and SV40 enhancer on hTERT promoter activity
To determine if plasmid vectors containing MMRE and SV40 enhancer could produce higher levels of transgene expression than those without them, a MMRE and a SV40 enhancer were inserted upstream and downstrem from the hTERT promoter respectively (Fig. 1C) . As shown in Fig 3B, pGL3 -MMRE-hT-enh with a MMRE and SV40 enhancer produced a more than 6-fold higher expression of luciferase than pGL3-hT with only the hTERT promoter in QBI-293A cells, and pGL3-hT-enh with a SV40 enhancer increased the level of expression more than 3-fold higher than pGL3-hT plasmid. But in the case of normal fibroblast Wi-38, there was no significant increase in hTERT promoter activity by MMRE and SV40 enhancer (Fig. 3A) . To show increased activity of the hTERT promoter by the MMRE sequence, c-Myc was overexpressed in QBI-293A as well as normal fibroblast Wi-38 cells, and luciferase assays were performed. In QBI-293A cells, the introduction of c-Myc expression vectors (pCMVc-myc) resulted in more than 2-fold activation. Recently, c-Myc has been reported to activate telomerase promoter in normal epithelial and fibroblast cells. 27) Similarly, in this study, c-Myc overexpression increased more than 3-fold the activation of hTERT transcription in Wi-38 (Fig. 3A) . NCI-H417 SCLC cells are known to overexpress c-Myc protein. 28) As shown in Fig. 4 , MMRE and SV40 enhancer increased the activity of hTERT promoter more than 17-fold without them in NCI-H417. These results showed that MMRE sequences and SV40 enhancer activated the hTERT promoter and can be used in SCLC treatment.
Ad-MMRE-hT-TK-enh confers more GCV sensitivity than Ad-hT-TK or Ad-hT-TK-enh to SCLC cells but does not affect normal fibroblasts
To determine increased cancer specific cell death by Ad-MMRE-hT-TK-enh, SCLC and normal fibroblast cell lines were infected with a moi of 50 of Ad-MMREhT-TK-enh, Ad-hT-TK-enh, Ad-hT-TK, and Ad-CMV with 50 mM of GCV (Fig. 5) . After 5 days of infection, Fig. 3 . Specific Increased Expression of Luciferase Gene Imparted by the MMRE, hTERT Promoter, and SV40 Enhancer.
pGL3-Con, pGL3-hT, pGL3-hT-enh, and pGL3-MMRE-hT-enh plasmids were introduced into normal fibroblast (A, Wi-38) and telomerase positive control cell line (B, QBI-293A). After transfection with c-Myc expression plasmid (pCMV-c-myc), the next day both cell lines were transfected with pGL3-MMRE-hT-enh plasmid (c-myc+mmhTenh). Relative luciferase activity was standardized with control plasmid pGL3-Control transfection. The means from at least three independent experiments are shown (Con, pGL3-Control; hT, pGL3-hT; hTenh, pGL3-hTenh; mmhTenh, pGL3-MMRE-hT-enh; c-myc, pCMV-c-myc); bars, SD.
Fig. 4. SCLC Specific Increased Expression of Luciferase Gene
Imparted by the MMRE, hTERT Promoter, and SV40 Enhancer. pGL3-Con, pGL3-hT, pGL3-hT-enh, and pGL3-MMRE-hT-enh plasmids were introduced into SCLC cells (NCI-H417). The means from at least three independent experiments are shown (Con, pGL3-Control; hT, pGL3-hT; hTenh, pGL3-hT-enh; mmhTenh, pGL3-MMRE-hT-enh); bars, SD. almost all the tumor cells displayed typical cell death, while they did not in Wi-38 cells. Ad-MMRE-hT-TKenh resulted in about 44% and 24% more cell death than Ad-hT-TK or Ad-hT-TK-enh infected cells respectively, but normal fibroblast Wi-38 was not affected by Ad-hT-TK, Ad-hT-TK-enh, or Ad-MMRE-hT-TK-enh.
Ad-MMRE-hT-TK-enh induced apoptosis of SCLC cells
The apoptotic cells in the Ad-MMRE-hT-TK-enh infected cells were analyzed by Cell Death Detection ELISA PLUS (Roche, Germany). The analysis showed that the Ad-MMRE-hT-TK-enh treated SCLC cells had undergone about 2.5-and 1.4-fold more apoptosis than that of Ad-hT-TK and Ad-hT-TK-enh respectively (Fig. 6) . Consequently, the experiment clearly indicated that Ad-MMRE-hT-TK-enh increased cell death by apoptosis of SCLC cells.
Discussion
In cancer gene therapy, restricted expression of the therapeutic gene in tumor is important. If the therapeutic gene is expressed in all cells, it will affect both tumor and normal cells. Using the tumor specific promoter system will solve this problem, but true tumor specific promoters are rare, and often these promoters are useful only for the particular types of cancers from which they are derived. Although telomerase activity is undetectable in most human somatic tissues, it is generally present in highly replicative tissues and in most human cancers. As such, its exclusive expression in most tumor cells makes it a very strong candidate for targeted cancer gene therapy. There are two kinds of telomeraseassociated cancer gene therapy for telomerase-positive tumors. 29) First, tumor cell growth is inhibited by direct inhibition of telomerase activity, resulting in apoptotic cell death or growth arrest. 30, 31) Telomerase consists of two major components, the RNA template (hTR) and the catalytic subunit (reverse transcriptase, hTERT). hTR is considered to be good therapeutic targets. 30, 31) The other approach is telomerase-specific cancer gene therapy using telomerase promoter as a means directly to kill telomerase positive tumors. [21] [22] [23] Although there are no clearly known mechanisms that control hTERT transcription, it is known that c-Myc has an important role in positive regulation of hTERT gene activation and telomerase activation. In previous studies, the c-Myc level directly influenced telomerase activity. 32) Telomerase activity in human leukemic cell lines is inhibited by antisense c-Myc oligonucleotide. 33) In the hTERT promoter region, there are two typical E-boxes (CACGTG, À165 to À160 and 42 to 48) which are known as potential binding sites of the c-Myc oncoprotein. 16) To investigate the possibility of the utilization of the hTERT promoter, MMRE, and SV40 enhancer in targeted SCLC gene therapy, adenovirus vector containing HSV-TK gene under the control of MMRE, hTERT promoter, and SV40 enhancer was constructed. This virus was introduced into normal fibroblast and SCLC cancer cell lines. After treatment, the morphology of the majority of the Ad-MMRE-hT-TK-enh infected SCLC cells changed into apoptotic cells and underwent cell death, but not normal fibroblasts. The growth of Ad-MMRE-hT-TK-enh infected cancer cells was significantly more suppressed than that of Ad-hT-TK or AdhT-TK-enh (Fig. 5) . Using a Cell Death Detection ELISA PLUS , the apoptotic cells of the Ad-MMRE-hT-TK-enh infected NCI-H417 cells were analyzed and it was found that the Ad-MMRE-hT-TK-enh treated cancer cells had undergone about 2.5-and 1.4-fold more apoptosis than that of Ad-hT-TK or Ad-hT-TK- enh (Fig. 6) . Therefore, it is concluded that the adenovirus Ad-MMRE-hT-TK-enh suppressed SCLC cell growth and induced apoptosis and, as such, might be a useful method for suppressing tumor growth in targeted cancer gene therapy. The existing cancer treatment method has limitations for elevation of the survival rate of cancer patients and has serious side effects on normal tissues and organs because of indiscriminate killing effects between normal and cancer cells. Therefore the technology of gene therapy, which can kill only tumor cells, is another alternative that can increase the rate of complete cure and the quality of life (QOL) of cancer patients. This is the first trial to use adenovirus vector, which has Myc-Max binding motifs, telomerase catalytic promoter hTERT, HSV-TK, and SV40 enhancer to suppress Myc and telomerase activity positive SCLC cells and induce apoptotic cell death. Adenovirus vector consisted of MMRE, hTERT promoter, SV40 enhancer, and suicide gene HSV-TK has the feature of maintaining the cancer specific character of the hTERT promoter and increased activated expression of HSV-TK by MMRE and SV40 enhancer, and it might be useful for targeted SCLC gene therapy.
